跳至主要内容
临床试验/NCT00163514
NCT00163514已完成3 期

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age

AstraZeneca75 个研究点 分布在 2 个国家目标入组 636 人开始时间: 2004年5月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
AstraZeneca
入组人数
636
试验地点
75
主要终点
changes in Total Nasal Symptom Score

研究概览

简要总结

The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double

入排标准

年龄范围
6 Years 至 11 Years(Child)
性别
All
接受健康志愿者

入选标准

  • General good health, other than perennial allergic rhinitis
  • History and diagnosis of perennial allergic rhinitis by skin prick test
  • Parent/caregiver must be capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent and comply with all study requirements (visits, record-keeping, etc.)

排除标准

  • Participation in any investigational drug trial within the 30 days preceding the Screening Visit or at any time during the trial
  • Use of any prohibited concomitant medications as defined by the study protocol
  • Non-vaccinated exposure to, or active infection with, chickenpox or measles within the 21 days preceding the Screening Visit

结局指标

主要结局

changes in Total Nasal Symptom Score

次要结局

  • safety, changes in symptoms

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (75)

Loading locations...

相似试验